Jeff Sevigny

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3.1K citations

Life Sciences, Neurology, Neuroscience +14

First‐in‐human, double‐blind, placebo‐controlled, single‐dose escalation study of aducanumab (BIIB037) in mild‐to‐moderate Alzheimer's disease

J L Ferrero, Leslie Williams, Heather Stella et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2016 · 181 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Patients with autism spectrum disorders display reproducible functional connectivity alterations

Štefan Holiga, Joerg F. Hipp, Christopher H. Chatham et al. · Science Translational Medicine · 2019 · 180 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

Federico Bolognani, Marta del Valle Rubido, Lisa Squassante et al. · Science Translational Medicine · 2019 · 127 citations

Medicine, Pharmacology, Pharmacotherapy +15

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials

Jeff Sevigny, Joyce Suhy, Ping Chiao et al. · Alzheimer Disease & Associated Disorders · 2016 · 115 citations

Medicine, Neurology, Nuclear Medicine +17